Tenders of Dak Gesundheit

Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 Sgb V for the active ingredient Maraviroc, Atc J05ax09 for the period January 1st, 2024 - December 31st, 2025

Conclusion of a non-exclusive discount agreement according to Section 130a Paragraph 8 Sgb V for the active ingredient Buserelin, Atc L02ae01 for the period January 1st, 2024 - December 31st, 2025

Conclusion of a non-exclusive discount agreement according to Section 130a Paragraph 8 Sgb V for the active ingredient Insulin Lispro, Atc A10ab04, A10ad04 FD Time 01/01/24 - 31/12/24 (plus extension option 1x12 months)

Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 Sgb V for the active ingredient Natalizumab (exclusively in the Dafo infusion solution concentrate), Atc L04aa23 for the period December 1st, 2023-November 30th, 2025 (1004084 - Natalizumab (exclusively in the kiln

Germany-hamburg: Pharmaceutical Products

Conclusion of a non-exclusive discount agreement according to Section 130a Paragraph 8 Sgb V for the active ingredient Clobetasol, Atc D07ad01 for the period December 1st, 2023 - November 30th, 2025 (1004083 - Clobetasol, Atc D07ad01)

Conclusion of a non-exclusive discount agreement according to Section 130a Paragraph 8 Sgb V for the active ingredient Distigmin, Atc N07aa03 for the period December 1st, 2023 - November 30th, 2025 (1004084 - Distigmin, Atc N07aa03)

Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 Sgb V for the active ingredient doravirin, lamivudine, tenofovir disoproxil fumarate, Atc J05ar24 for the period December 1st, 2023 - November 30th, 2025 (1004084 - doravirin, lamivudine, tenofovir disoproxil fumarate,

Conclusion of a non-exclusive discount agreement according to Section 130a Paragraph 8 Sgb V for the active ingredient Doravirin, Atc J05ag06 for the period December 1st, 2023 - November 30th, 2025 (1004084 - Doravirin, Atc J05ag06)

Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 Sgb V for the active ingredient Tocilizumab, Atc L04ac07 for the period December 1st, 2023 - November 30th, 2024 (plus extension option 1x12 months) (1004084 - Tocilizumab (exclusively pre-filled syringe and